Research Article
Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
Table 2
Outcomes after switching to aflibercept in patients with neovascular AMD.
| | All (, year 1; 118, year 2; 58, year 3) | | Group 1 bevacizumab (, year 1; 66, year 2; 22, year 3) | | Group 2 ranibizumab (, year 1; 52, year 2; 36, year 3) | |
| BCVA, ETDRS score | Before switch | 56.5 ± 15.7 | | 56.5 ± 16.8 | | 56.3 ± 13.9 | | After 1 year | 54.6 ± 19.0 | 0.027 | 54.8 ± 19.8 | 0.108 | 54.3 ± 17.9 | 0.127 | After 2 years | 54.6 ± 16.7 | 0.001 | 57.3 ± 16.2 | 0.163 | 51.2 ± 16.9 | 0.001 | After 3 years | 50.3 ± 19.1 | <0.001 | 50.8 ± 22.3 | 0.016 | 50.1 ± 17.2 | 0.001 | CRT, μm | Before switch | 386.2 ± 163.7 | | 406.7 ± 184.4 | | 370.7 ± 163.8 | | After 1 year | 313.2 ± 140.9 | <0.001 | 329.7 ± 152.6 | <0.001 | 287.5 ± 116.8 | <0.001 | After 2 years | 280.2 ± 121.3 | <0.001 | 270.0 ± 107.3 | <0.001 | 293.1 ± 137.1 | <0.001 | After 3 years | 266.1 ± 123.5 | <0.001 | 259.4 ± 85.7 | <0.001 | 269.7 ± 140.9 | <0.001 | Injections per year, n | In the first year | 7.8 ± 2.6 | | 8.0 ± 2.6 | | 7.8 ± 2.1 | | In the second year | 6.8 ± 3.5 | 0.007 | 7.5 ± 3.5 | 0.219 | 6.1 ± 3.2 | <0.001 | In the third year | 6.5 ± 3.1 | 0.002 | 7.3 ± 2.8 | 1 | 5.9 ± 3.1 | <0.001 |
|
|
Outcomes are expressed as mean values ± SD.
|